This is the Artificial Heart of the Future

Unlike other TAHs, Carmat’s heart can modify the flow rate of blood in real time according to demand. For instance, during exercise the heart would increase the flow. It should be able to operate, allowing the user to lead a normal lifestyle, for up to 5 years. Although the device has been in development for 27 years, it just received the CE Mark in Europe (the equivalent of FDA approval in the U.S.). It still must receive FDA approval before it can be sold in the U.S. Until then, SynCardia’s artificial heart will remain the only option on the market.